Gregory K. Friedman

3.1k total citations
99 papers, 2.0k citations indexed

About

Gregory K. Friedman is a scholar working on Genetics, Oncology and Molecular Biology. According to data from OpenAlex, Gregory K. Friedman has authored 99 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Genetics, 40 papers in Oncology and 36 papers in Molecular Biology. Recurrent topics in Gregory K. Friedman's work include Virus-based gene therapy research (39 papers), CAR-T cell therapy research (31 papers) and Glioma Diagnosis and Treatment (29 papers). Gregory K. Friedman is often cited by papers focused on Virus-based gene therapy research (39 papers), CAR-T cell therapy research (31 papers) and Glioma Diagnosis and Treatment (29 papers). Gregory K. Friedman collaborates with scholars based in United States, Germany and United Kingdom. Gregory K. Friedman's co-authors include G. Yancey Gillespie, James M. Markert, Joshua D. Bernstock, Kevin A. Cassady, Elizabeth A. Beierle, Xiaosi Han, Anita B. Hjelmeland, Paul M. Foreman, Virginia Kelly and Catherine P. Langford and has published in prestigious journals such as Journal of Clinical Investigation, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Gregory K. Friedman

96 papers receiving 2.0k citations

Peers

Countries citing papers authored by Gregory K. Friedman

Since Specialization

Citations

This map shows the geographic impact of Gregory K. Friedman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gregory K. Friedman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gregory K. Friedman more than expected).

Fields of papers citing papers by Gregory K. Friedman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gregory K. Friedman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gregory K. Friedman. The network helps show where Gregory K. Friedman may publish in the future.

Co-authorship network of co-authors of Gregory K. Friedman

This figure shows the co-authorship network connecting the top 25 collaborators of Gregory K. Friedman. A scholar is included among the top collaborators of Gregory K. Friedman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gregory K. Friedman. Gregory K. Friedman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Case Report: Low-grade glioma with NF1 loss of function mimicking diffuse intrinsic pontine glioma 2024 ·Frontiers in Surgery ·Joshua D. Bernstock, Paramesh Karandikar, Jason Chen, Jakob Seidlitz, Gregory K. Friedman, David M. Meredith, Kevin X. Liu, Daphne A. Haas‐Kogan, David A. Reardon, Pier Paolo Peruzzi	1
2	Combination Immunotherapy with Vaccine and Oncolytic HSV Virotherapy Is Time Dependent 2024 ·Molecular Cancer Therapeutics ·Stacie K. Totsch, Andrew S. Ishizuka, Kyung‐Don Kang, Sam E. Gary, (unknown), (unknown), (unknown), Pablo A. Valdés, (unknown), (unknown), Luca Peruzzotti‐Jametti, Sarah E. Blitz, (unknown), James M. Johnston, James M. Markert, Geoffrey M. Lynn, Joshua D. Bernstock, Gregory K. Friedman	3
3	Leveraging next-generation materials for cancer neuroscience therapies in the central nervous system 2024 ·Nature Reviews Materials ·Joshua D. Bernstock, Benjamin R. Johnston, Gregory K. Friedman, E. Antonio Chiocca, Róbert Langer, Shriya S. Srinivasan	5
4	Positioning SUMO as an immunological facilitator of oncolytic viruses for high-grade glioma 2023 ·Frontiers in Cell and Developmental Biology ·Paramesh Karandikar, (unknown), Jakob V. E. Gerstl, Sarah E. Blitz, (unknown), Sae‐Yeon Won, Florian Geßler, Omar Arnaout, Timothy R. Smith, Pierpaolo Peruzzi, (unknown), Gregory K. Friedman, Joshua D. Bernstock	2
5	Modeling of intracranial tumor treating fields for the treatment of complex high-grade gliomas 2023 ·Scientific Reports ·David J. Segar, Joshua D. Bernstock, Omar Arnaout, Wenya Linda Bi, Gregory K. Friedman, Robert Langer, Giovanni Traverso, Sumientra Rampersad	11
6	Recent oncolytic virotherapy clinical trials outline a roadmap for the treatment of high-grade glioma 2023 ·Neuro-Oncology Advances ·Joshua D. Bernstock, Sarah E. Blitz, Samantha E. Hoffman, Jakob V. E. Gerstl, E. Antonio Chiocca, Gregory K. Friedman	6
7	Intraventricular immunovirotherapy; a translational step forward 2023 ·Oncotarget ·Joshua D. Bernstock, Sarah E. Blitz, Kyung‐Don Kang, Gregory K. Friedman	5
8	Positioning Transclival Tumor-Treating Fields for the Treatment of Diffuse Intrinsic Pontine Gliomas 2023 ·Life ·Walid Ibn Essayed, Casey A. Jarvis, Joshua D. Bernstock, (unknown), (unknown), Gregory K. Friedman, Omar Arnaout, Lissa Baird	3
9	Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers 2022 ·Clinical Cancer Research ·Kyung‐Don Kang, Joshua D. Bernstock, Stacie K. Totsch, Sam E. Gary, (unknown), Li Nan, Rong Li, (unknown), Xiaosi Han, Elizabeth A. Beierle, Tanja Eisemann, Robert J. Wechsler‐Reya, Sejong Bae, Richard J. Whitley, G. Yancey Gillespie, James M. Markert, Gregory K. Friedman	11
10	Immunovirotherapy for the Treatment of Glioblastoma and Other Malignant Gliomas 2021 ·Neurosurgery Clinics of North America ·Dagoberto Estévez-Ordoñez, Gustavo Chagoya, Arsalaan Salehani, (unknown), (unknown), (unknown), Galal Elsayed, Anil Mahavadi, (unknown), Gregory K. Friedman, James M. Markert	19
11	Design and Rationale for First-in-Human Phase 1 Immunovirotherapy Clinical Trial of Oncolytic HSV G207 to Treat Malignant Pediatric Cerebellar Brain Tumors 2020 ·Human Gene Therapy ·Joshua D. Bernstock, Asim K. Bag, John B. Fiveash, Kara Kachurak, Galal Elsayed, Gustavo Chagoya, Florian Geßler, Pablo A. Valdés, Avi Madan‐Swain, Richard J. Whitley, James M. Markert, G. Yancey Gillespie, James M. Johnston, Gregory K. Friedman	32
12	SUMOylation promotes survival and integration of neural stem cell grafts in ischemic stroke 2019 ·EBioMedicine ·Joshua D. Bernstock, Luca Peruzzotti‐Jametti, Tommaso Leonardi, Nunzio Vicario, Daniel Ye, Yang-ja Lee, Dragan Maric, Kory R. Johnson, Yongshan Mou, Aletta M.R. van den Bosch, Mark S. Winterbone, Gregory K. Friedman, Robin J.M. Franklin, John M. Hallenbeck, Stefano Pluchino	45
13	Characterization of iPSCs derived from low grade gliomas revealed early regional chromosomal amplifications during gliomagenesis 2018 ·Journal of Neuro-Oncology ·Zhong Liu, Pulin Che, (unknown), James R. Hackney, Gregory K. Friedman, Cheng Zhang, Zhiying You, Xinyang Zhao, Qiang Ding, Kitai Kim, Hu Li, Margaret Liu, James M. Markert, Burt Nabors, G. Yancey Gillespie, Rui Zhao, Xiaosi Han	14
14	Rationale and Design of a Phase 1 Clinical Trial to Evaluate HSV G207 Alone or with a Single Radiation Dose in Children with Progressive or Recurrent Malignant Supratentorial Brain Tumors 2017 ·PubMed ·Alicia M. Waters, James M. Johnston, Alyssa Reddy, John B. Fiveash, Avi Madan‐Swain, Kara Kachurak, Asim K. Bag, G. Yancey Gillespie, James M. Markert, Gregory K. Friedman	45
15	Rationale and Design of a Phase I Clinical Trial to Evaluate HSV G207 Alone or with a Single Radiation Dose in Children with Progressive or Recurrent Malignant Supratentorial Brain Tumors 2017 ·Alicia M. Waters, James M. Johnston, Alyssa Reddy, John B. Fiveash, Avi Madan‐Swain, Kara Kachurak, Asim K. Bag, G. Yancey Gillespie, James M. Markert, Gregory K. Friedman	3
16	Effect of Repeat Dosing of Engineered Oncolytic Herpes Simplex Virus on Preclinical Models of Rhabdomyosarcoma 2016 ·Translational Oncology ·Alicia M. Waters, (unknown), (unknown), (unknown), Jerry E. Stewart, Gregory K. Friedman, Jennifer Coleman, James M. Markert, G. Yancey Gillespie, Elizabeth A. Beierle	8
17	Pediatric cancer gone viral. Part I: strategies for utilizing oncolytic herpes simplex virus-1 in children 2015 ·Molecular Therapy — Oncolytics ·Timothy P. Cripe, Chun‐Yu Chen, Nicholas Denton, Kellie B. Haworth, Brian Hutzen, Jennifer L. Leddon, Keri A. Streby, Pin-Yi Wang, James M. Markert, Alicia M. Waters, G. Yancey Gillespie, Elizabeth A. Beierle, Gregory K. Friedman	20
18	Preclinical Evaluation of Engineered Oncolytic Herpes Simplex Virus for the Treatment of Pediatric Solid Tumors 2014 ·PLoS ONE ·(unknown), (unknown), Jerry E. Stewart, (unknown), Elizabeth Mroczek‐Musulman, Alicia M. Waters, Jennifer Coleman, Virginia Kelly, James M. Markert, G. Yancey Gillespie, Gregory K. Friedman, Elizabeth A. Beierle	15
19	Treatment of Children With Glioblastoma With Conformal Radiation, Temozolomide, and Bevacizumab as Adjuncts to Surgical Resection 2013 ·Journal of Pediatric Hematology/Oncology ·Gregory K. Friedman, (unknown), (unknown), John B. Fiveash, Alyssa Reddy	6
20	Changing trends of research and treatment in infant neuroblastoma 2007 ·Pediatric Blood & Cancer ·Gregory K. Friedman, Robert P. Castleberry	24

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact